CASE REPORT

Galactose treatment of a PGM1 patient presenting with restrictive cardiomyopathy

Sarah E. Donoghue1,2 | Susan M. White2,3 | Tiong Yang Tan2,3 | Remi Kowalski4 | Eva Morava5,6 | Joy Yaplito-Lee1,3

1Department of Metabolic Medicine, Royal Children’s Hospital, Melbourne, Victoria, Australia
2Victorian Clinical Genetics Services, Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
3Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
4Department of Cardiology, Royal Children’s Hospital, Melbourne, Victoria, Australia
5Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota
6Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium

Correspondence
Dr Sarah E. Donoghue, Royal Children’s Hospital, 50 Flemington Road, Parkville, VIC 3052, Australia.
Email: sarah.donoghue@rch.org.au

1 INTRODUCTION

Congenital disorders of glycosylation (CDG) are a group of genetic metabolic conditions that alter protein glycosylation.1 Phosphoglucomutase deficiency (PGM1-CDG) has important roles in glycogenolysis and glyconeogenesis as it catalyzes the bidirectional conversion of glucose 1-phosphate and glucose 6-phosphate.1-3 In addition to the maintenance of glucose homeostasis, PGM1-CDG has a role in protein N-linked glycosylation, which is very important in post-translational modification.4 The defects in glycosylation affect transport proteins, coagulation factors and organ system development.4,5 Previously reported features of PGM1-CDG included hepatopathy, hypoglycemia, congenital craniofacial malformations, myopathy, coagulopathy, endocrine deficiencies, dilated cardiomyopathy, strabismus, seizures and intellectual disability.6

Oral D-galactose supplementation has been trialed in patients with PGM1 deficiency, which demonstrated beneficial effects in glycosylation with both transferrin isoelectric focusing and in vitro studies examining fibroblasts.2,7 Other reported benefits from this trial included normalization or improvement of abnormal coagulation and liver function abnormalities.7 It has also been demonstrated that D-galactose supplementation is

Abstract
We report a patient diagnosed with PGM1-CDG at 11 years of age after two biallelic likely pathogenic variants in PGM1 were found on research genomic sequencing. To our knowledge, he is the first patient with PGM1-CDG to be reported with a restrictive cardiomyopathy. Other clinical manifestations included cleft palate, asymptomatic elevated transaminases, intellectual disability and myopathy resulting in exercise intolerance. He was trialed on oral galactose therapy in increasing doses for 18 weeks to assess if there was any biochemical and clinical benefit. His galactose was continued for a further 9 months beyond the initial galactose treatment period due to improvements in exercise tolerance and myopathy. Treatment with galactose demonstrated an improvement in liver function and myopathy with improved exercise tolerance. Treatment with galactose for 15 months did not change heart function and exercise stress test results were stable.

KEYWORDS
galactose, PGM1-CDG, restrictive cardiomyopathy

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. JIMD Reports published by John Wiley & Sons Ltd on behalf of SSIEM.

JIMD Reports. 2021;57:29–37.

wileyonlinelibrary.com/journal/jmd2
safe when given orally in doses of 1.5 g/kg/day up to a maximum dose of 50 g daily.7

2 | CASE REPORT

Our patient is the second child of three children born to non-consanguineous Caucasian parents. During pregnancy, an increased nuchal translucency was detected of greater than 6 mm and short long bones were identified on a first trimester ultrasound performed at 13 weeks of gestation. He was born at 36 weeks of gestation via normal vaginal delivery, with birth weight 3 kg (17.76th centile, \( Z = -0.92 \)), length 46 cm (6.86th centile, \( Z = -1.49 \)) and head circumference 33.6 cm (14.33th centile, \( Z = -1.07 \)). There is a family history of learning difficulties affecting his parents, brother and extended family members.

He was diagnosed with a midline cleft palate postnatally and required readmission due to feeding difficulties. Distinctive features were noted including a round face, depressed nasal bridge, simple morphology to the ears and thin eyebrows, features which were shared by his mother. His midface was noted to be relatively hypoplastic compared to his family members. He had bilateral single palmar creases and short fifth fingers. Further investigations at the time revealed an atrial septal defect measuring 8 mm. A skeletal survey at 1 month of age showed mild epiphyseal delay and slight rounding of vertebral bodies.

There were growth concerns in the first 12 months of life and a gastrostomy was inserted at 14 months of age because of failure to thrive. This was removed at 18 months following palate repair and an improvement in growth. His weight crossed centiles and regained to the 5th centile, however his length remained on the 1st centile until 10 years of age when his growth velocity improved. At 12 years of age, he reached the 17th centile for height and weight increased to the 60th centile.

A restrictive cardiomyopathy was diagnosed at 5 years of age after previous earlier follow-up echocardiograms demonstrated no cardiomyopathy. Serial echocardiography demonstrated normal left and right ventricular function in the context of a dilated left atrium. Cardiac magnetic resonance imaging (MRI) was performed at age 11 years demonstrating no pericardial involvement. His echocardiogram demonstrated a mild reduction in systolic function after the age of 11 years and he developed features of a combined restrictive and dilated cardiomyopathy (DCM) with predominance of restrictive form in the next 6 months. The evolution of the echocardiogram findings is summarized in Table 1.

Brain MRI at age 10 years was normal. Our patient had a normal banded karyotype and FISH testing for 22q11.21 in the neonatal period. Microarray showed a maternally inherited 0.2 Mb duplication of chromosome 5q35.5 that was novel. The duplication contained PROPI, in which biallelic mutations have been associated with hypopituitarism, and three other genes whose function is unknown. The significance of this duplication is unknown. A cardiomyopathy gene panel encompassing 63 cardiomyopathy genes did not identify any pathogenic variants.

Further research genomic testing by a custom-designed Agilent SureSelect craniofacial panel comprising 79 genes as described previously by Tan et al8 at age 11 years identified a previously reported variant in the PGM1 gene, c.1042 G>C, p.(Gly348Arg) and a novel variant c. 1051 C>T, p.(Arg351Trp). Visual inspection of sequencing reads on IGV confirmed that the variants were in trans. Both variants are present in heterozygous state in low frequencies in the gnomAD population database, and have not been reported in affected individuals. Both variants affected residues located within the PGM_PMM_III functional domain of the PGM1 protein and both amino acid residues are highly conserved. In silico software predictions that the variants were both disease causing. Using the American College of Medical Genetics for assessing pathogenicity described by Richards et al9 both variants were classified as likely pathogenic. Serum transferrin isoforms performed at the age of 11 years old were abnormal with elevated disialotransferrin and decreased tetrasialotransferrin.

The patient was started on n-galactose age 12 years with increasing dosage as per Table 1. The galactose supplementation was continued beyond week 18 for a period of 9 months. One examiner (SD) performed clinical examination and scoring according to the Tulane PGM1-CDG Rating Scale (TPCRS) that was previously used by Wong et al6 to define phenotype and severity. Clinical evaluation, laboratory studies and assessments were followed as per Table 1.

Synopsis

Presentation with a restrictive cardiomyopathy may be a clinical feature of PGM1-CDG.
RESULTS

Galactose supplementation was well tolerated with no reportable adverse events. Serial measures with the TPCR demonstrated an improvement in the score. This was mainly due to improvement in myopathy and hearing where he no longer required hearing aids due to improvements on serial audiology assessments. During the period of galactose supplementation, our patient reported improved exercise tolerance, a reduction in muscle pain and improved quality of life as he was now able to run and participate in low impact sporting activities and walking. His muscle strength also significantly improved on clinical assessment. Creatine kinase (CK) levels fluctuated through the study and did not correlate to clinical symptoms (Table 2).

The distance walked on the 6-minute walk test (6MWT) was improved by 20% with consistent galactose supplementation. Three months following the initial 18-week period of treatment, our patient was not always compliant with treatment and despite walking less distance on the 6MWT, he did not have any recurrence of myopathy or myalgia. Serial echocardiogram was stable throughout the study. Exercise treadmill testing demonstrated a small improvement.

Biochemical parameters such as full blood count, renal function, thyroid function and copper and caeruloplasmin remained stable. The liver function demonstrated an improvement in transaminases and abdominal ultrasound demonstrated mild hepatomegaly on imaging at baseline and 18 weeks of treatment. On treatment, our patient demonstrated emergence of mild abnormalities on his coagulation, but these did not manifest as clinical events. The serum transferrin isoforms initially normalized on treatment with oral galactose, with the tetrasialotransferrin normalizing during the first 6 weeks of treatment and the disialotransferrin normalizing in the first 12 weeks of treatment. When galactose therapy was not maintained at the 3 months maintenance dose of galactose the transferrin isoforms demonstrated a type 1 CDG pattern with an increase in disialotransferrin and a decreased tetrasialotransferrin level.

DISCUSSION

We report the effects of oral galactose supplementation in a 12-year-old patient with genetically confirmed PGM1 deficiency who was diagnosed at the age of 11 years by research genomic sequencing with abnormal serum transferrin isoelectric focussing confirming a type 1 CDG pattern.

### TABLE 1  Evolution of initial echocardiogram findings in patient with PGM1-CDG

| Age | Echocardiogram | 3.5 years | 5.5 years | 6 years | 8 years | 10 years |
|-----|----------------|-----------|-----------|---------|---------|---------|
| LVEDd (cm) | 3.4 | 4.0 | 4.5 | 4.6 | 4.7 |
| Normal range | 2.3 to 3.4 | 2.9 to 3.9 | 2.9 to 4.0 | 3.1 to 4.2 | 3.4 to 4.7 |
| Z-score | 1.9 | 2.7 | 3.8 | 3.5 | 2.0 |
| Fractional shortening (%) | 32.2 | 33.6 | 31.1 | 26.7 | 33.8 |
| EF (%) | 61.6 | 65.2 | 59 | 51.3 | 54.1 |
| Septal thickness (cm) | 0.49 | 0.56 | 0.40 | 0.7 | 0.67 |
| Normal range | 0.25 to 0.67 | 0.33 to 0.7 | 0.26 to 0.79 | 0.35 to 0.75 | 0.35 to 0.79 |
| Z-score | 0.28 | 0.51 | −0.93 | 1.5 | 0.33 |
| Atrial dilation | Normal size | Normal RA size | Mild RA dilation | Severe LA dilation with septal bowing | Normal RA size |
| RUV A wave reversal velocity (cm/s) | — | 78.2 cm/s | — | — | 66 |
| MV E/A ratio | 3.0 | 1.5 | — | — | 2.2 |
| Tissue Doppler velocities | Normal | Normal | Normal | Normal | Normal |

Abbreviations: EF, ejection fraction; LA, left atrium; LVEDd, left ventricular end diastolic dimension; RA, right atrium; RUPV, right upper pulmonary vein.
| Parameter          | Baseline | 6 wk     | 12 wk    | 18 wk    | 3 mo maintenance | 6 mo maintenance | 9 mo maintenance |
|--------------------|----------|----------|----------|----------|------------------|------------------|------------------|
| Galactose dose     | —        | 0.5 g/kg/d | 1 g/kg/d | 50 g daily | 50 g daily       | 50 g daily       | 50 g daily       |
| Clinical scoring   |          |          |          |          |                  |                  |                  |
| Tulane PGM1-CDG rating scale | 12 | 10     | 10     | 8       | 9                | 9                | 8                |
| I. Current function |         |          |          |          |                  |                  |                  |
| Vision             | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Hearing            | 1        | 1        | 1        | 0        | 0                | 0                | 0                |
| Communication      | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Feeding            | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Mobility           | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| II. System specific involvement | | | | | | | |
| Seizures           | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Encephalopathy     | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Haemostatic        | 1        | 1        | 1        | 1        | 1                | 1                | 1                |
| Gastrointestinal   | 1        | 0        | 0        | 0        | 0                | 0                | 0                |
| Endocrine          | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Respiratory        | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Cardiac            | 2        | 2        | 2        | 2        | 2                | 2                | 2                |
| Renal              | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Liver              | 1        | 1        | 1        | 1        | 1                | 1                | 1                |
| Blood              | 0        | 1        | 1        | 1        | 1                | 0                | 0                |
| Congenital malformation | 3 | 3        | 3        | 3        | 3                | 3                | 3                |
| III. Current clinical assessment | | | | | | | |
| Growth             | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Vision with glasses| 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Strabismus, abnormal eye movement | 1 | 1        | 1        | 1        | 1                | 1                | 1                |
| Myopathy           | 2        | 1        | 0        | 0        | 0                | 0                | 0                |
| Ataxia             | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Pyramidal          | 0        | 0        | 0        | 0        | 0                | 0                | 0                |
| Parameter                  | Baseline | 6 wk | 12 wk | 18 wk | 3 mo maintenance | 6 mo maintenance | 9 mo maintenance |
|---------------------------|----------|------|-------|-------|-----------------|-----------------|-----------------|
| Extrapyramidal            | 0        | 0    | 0     | 0     | 0               | 0               | 0               |
| Neuropathy                | 0        | 0    | 0     | 0     | 0               | 0               | 0               |
| Weight kg (centile)       | 41.8 (58th) | 43.3 (62nd) | 43.4 (60th) | 44.7 (63rd) | 45.5 (62nd) | 48 (66th) | 50 (68th) |
| Height cm (centile)       | 140 (12th) | 142.1 (17th) | 142.1 (14th) | 143 (15th) | 144.4 (15th) | 146.8 (17th) | 148.3 (17th) |

### Pathology

#### Full blood count

| Parameter                  | Baseline | 6 wk | 12 wk | 18 wk | 3 mo maintenance | 6 mo maintenance | 9 mo maintenance |
|---------------------------|----------|------|-------|-------|-----------------|-----------------|-----------------|
| Hemoglobin (120-160)      | 118      | 115  | 116   | 115   | 119             | 121             | 121             |
| Platelets (150-400)       | 179      | 161  | 214   | 164   | 164             | 208             | 171             |
| White cells               | Normal   | Normal | Normal | Normal | Normal         | Normal          | Normal          |
| Electrolytes, urea,      | N        | N    | N     | N     | N               | N               | N               |
| creatinine                |          |      |       |       |                 |                 |                 |
| TSH (0.5-4.5 mIU/L)       | 1.88     | 2.1  | 3.76  | 3.4   | 2.1             | 3.21            | 4.06            |

#### Coagulation testing

| Parameter                  | Baseline | 6 wk | 12 wk | 18 wk | 3 mo maintenance | 6 mo maintenance | 9 mo maintenance |
|---------------------------|----------|------|-------|-------|-----------------|-----------------|-----------------|
| INR (0.8-1.2)             | 1.1      | 1.2  | 1.2   | 1.2   | 1.1             | 1.4             | 1.2             |
| APTT (27-44 s)            | 40       | 38   | 41    | 41    | 42              | 39              |                 |
| Fibrinogen (1.5-4.3 g/L)  | 2.7      | 3.2  | 3.3   | 2.6   | 3.2             | 2.7             |                 |
| PT (11.5-14.5 s)          | —        | —    | —     | —     | —               | —               | 14.7            |
| Anti-thrombin III (70%-140%) | —      | 75   | 87    | 98    | 55              | 69              |                 |
| Factor XI (60%-180%)      | 55       | 65   | 56    | 95    | 29              | 88              |                 |
| Factor IX (60%-200%)      | 112      | 122  | 96    | 98    | 85              | 69              |                 |

#### Liver function tests

| Parameter                  | Baseline | 6 wk | 12 wk | 18 wk | 3 mo maintenance | 6 mo maintenance | 9 mo maintenance |
|---------------------------|----------|------|-------|-------|-----------------|-----------------|-----------------|
| ALT (10-35)               | 95       | 61   | 45    | 47    | 63              | 46              | 57              |
| ALP (100-350)             | 190      | 163  | 206   | 187   | 211             | 174             | 167             |
| GGT (0-40)                | 16       | 17   | 16    | 19    | 15              | 19              | 20              |
| Lactate dehydrogenase (313-618) | 515     | 179  | 237   | 196   | 230             | 203             | 187             |
| Creatine kinase (40-240 U/L) | 258     | 306  | 1431  | 295   | 1002            | 838             | 303             |
| Lipid profile             | N        | N    | N     | N     | N               | N               | N               |

(Continues)
| Parameter                        | Baseline | 6 wk | 12 wk | 18 wk | 3 mo maintenance* | 6 mo maintenance | 9 mo maintenance |
|---------------------------------|----------|------|-------|-------|-------------------|------------------|------------------|
| Copper                          | N        | N    | N     | N     | N                 | N                | N                |
| Caeruloplasmin                  | N        | N    | N     | N     | N                 | N                | N                |
| IGFI (16.52-65.33 nmol/L)       | 19       | 29.6 | 31.1  | 39    | 19.7              | 31               | 25.7             |
| IgFB3 (85.7-211.9 nmol/L)       | —        | 109.7| 104.3 | 121.1 | 84.7              | 116              | 107              |

**Serum transferrin isoforms**

| Disialotransferrin (0-3)        | 14       | 5    | 3     | 2.3   | 12.8              | 5.7              | 5.3              |
| Trisialotransferrin (0-8)       | 6        | 5.4  | 4.9   | 4.4   | 7.8               | 6.3              | 5.2              |
| Tetrasialotransferrin (71-84)   | 68       | 71   | 77    | 78    | 64                | 73               | 74               |
| Pentasialotransferrin (10-20)   | 12       | 19   | 15    | 16    | 15                | 15               | 15               |

**Imaging and functional tests**

| 6-min walk test (m)             | 41.5     | 447  | 428   | 490   | 460              | 465              | 499              |

**Echocardiogram**

| LVEDd (cm)                      | 5.3      | 5.2  | 5.2   | 5.4   |                  |                  |                  |
| Normal range                    | 3.6 to 5.0| 3.7 to 5.1| 3.8 to 5.2| 2.5   |                  |                  |                  |
| Z-score                         | 2.9      | 2.2  | 3.1   | 34.9  |                  |                  |                  |
| Fractional shortening (%)       | 29.1     | 31.1 |       |       |                  |                  |                  |
| EF (%)                          | 55.5     | 58.4 | 63.6  | 64.6  |                  |                  |                  |
| Septal thickness (cm)           | 0.48     | 0.74 | 0.42 to 0.99| 0.44 to 1.0| 0.66           |                  |                  |
| Z-score                         | −1.3     | 0.29 | −0.43 |       |                  |                  |                  |
| Atrial dilatation               | Normal RA size | Normal RA size | Normal RA size | Normal RA size | Normal RA size |                  |                  |
|                                | Severe LA dilatation with rightward septal bowing | Severe LA dilatation with rightward septal bowing | Severe LA dilatation with rightward septal bowing | Severe LA dilatation with rightward septal bowing |                  |                  |
|                                | 55.9     | 61.5 | 91    |       |                  |                  |                  |
Our patient was treated with oral galactose supplementation for 15 months without reporting any significant side-effects. This safety information is consistent with other case studies and cohorts of patients who have been treated with oral \(\alpha\)-galactose supplementation.\(^7,10\)

Our patient had an improvement in his exercise tolerance and muscle pain on galactose therapy. This demonstrates a similar benefit to other patients where their functional data has been measured on galactose supplementation.\(^10\) Despite fluctuation in the CK levels, the patient remained asymptomatic without any reported myalgia, which is similar to what has been reported in previous studies.\(^7,10\) Our patient is the first reported patient to present with an initial restrictive cardiomyopathy evolving subsequently into a combined restrictive and dilated cardiomyopathy. He had received serial echocardiograms from infancy to monitor closure of his atrial septal defect that did not demonstrate any features of cardiomyopathy prior to the first echocardiogram demonstrating a restrictive cardiomyopathy when he was 5 years old. DCM is the most common type of cardiac anomaly in PGM1, detected in 12 out of the 57 patients reported up till now with PGM1-CDG.\(^4,5,7,10-14\) The finding of the initial restrictive cardiomyopathy in our patient may demonstrate that there is a broader cardiac phenotype in patients with PGM1-CDG. Our patient described that prior to galactose supplementation his exercise tolerance had been limited by myalgia, but following the supplementation it was limited by dyspnea. Galactose did not demonstrably improve the echocardiogram or ECG results in our patient. The improvement on the serial audiology screening cannot be easily explained and may be due to less episodes of otitis media during warmer weather.

Intellectual disability has been reported in other patients with PGM1-CDG.\(^11,15,16\) Our patient was diagnosed with a mild intellectual disability, but as other family members have been diagnosed with an intellectual disability this may be multifactorial. The significance of the novel chromosome duplication is also unclear. Similarly, the dysmorphic features in our patient may be familial, as he shared a close resemblance to his mother. We consider it most likely that our patient’s dysmorphic features and learning difficulties are familial traits, while his cleft palate, midface hypoplasia, atrial septal defect and cardiomyopathy are due to his PGM1-CDG.

Our patient demonstrated normal levels of TSH, IGF1 and IGFB3 at the outset of the study and these remained essentially normal with treatment, meaning that we were unable to demonstrate the same improvements in glycosylation as seen in in previous patients on galactose supplementation.\(^7\) He also demonstrated improvements in his liver function, which is similar to other patients that

| Parameter                  | Baseline | 6 wk    | 12 wk   | 18 wk   | 3 mo maintenance | 9 mo maintenance | 6 mo maintenance | 9 mo maintenance | 6 mo maintenance | 9 mo maintenance |
|----------------------------|----------|---------|---------|---------|------------------|------------------|------------------|------------------|------------------|------------------|
| RUV A wave reversal velocity (cm/s) | 2.0      | Normal  | Normal  | Normal  | 2.1              | 2.1              | 2.1              | 2.1              | 2.1              | 2.1              |
| MV E/A ratio               |          |         |         |         |                  |                  |                  |                  |                  |                  |
| Tissue Doppler velocities |          |         |         |         |                  |                  |                  |                  |                  |                  |
| Normal liver ultrasound, no hepatomegaly | 13.2 cm |         |         |         |                  |                  |                  |                  |                  |                  |
| 7 min modified Bruce protocol |          |         |         |         |                  |                  |                  |                  |                  |                  |

**TABLE 2 (Continued)**

**Abbreviations:** LVEDd, left ventricular end diastolic dimension; EF, ejection fraction; RA, right atrium; LA, left atrium.

*Non-compliance with daily supplementation when reviewed.

Growth measured using — CDC Boys 2 to 20 year old growth charts.
have been previously reported. In contrast to some of the previously reported patients, our patient started with normal coagulation parameters (international normalised ratio [INR], activated partial thromboplastin time [APTT], fibrinogen and prothrombin time) and demonstrated mild derangement on longer term galactose supplementation. His baseline factor XI was low and the improvement of his levels was not always maintained even when he was compliant with supplementation. These coagulation abnormalities did not manifest in significant bleeding events, but this demonstrates that glycosylated proteins should be monitored and potentially still requires treatment in patients who remain on long-term galactose supplementation. The difficulty in maintaining long-term correction of glycosylation has previously been reported and it may reflect that higher doses of galactose may be required for longer term correction.

5 CONCLUSION

Although dilated cardiomyopathy is well reported in PGM1-CDG, we have reported the first case of a restrictive cardiomyopathy evolving into a combined restrictive and dilated cardiomyopathy. Treatment with galactose in PGM1-CDG improves liver function, myopathy and exercise tolerance. Transferrin isoforms can normalize on supplementation with oral galactose. Galactose seems to be reasonably well tolerated; however, normal glycosylation may not necessarily be achieved on smaller doses of galactose and this means that glycosylated proteins may still require monitoring and treatment.

ACKNOWLEDGMENTS

The authors would like to acknowledge Ms Mary Egginton and Dr James Pitt from the metabolic laboratory at Victorian Clinical Genetic Service for performing the serum transferrin isoforms.

CONFLICT OF INTEREST

Sarah Donoghue, Susan White, Tiong Tan, Remi Kowalski, Eva Morava and Joy Yapligo-Lee declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

All authors contributed to manuscript preparation. Sarah E. Donoghue was involved in the clinical assessment of the patient and follow up of galactose therapy. Susan M. White and Tiong Yang Tan were involved in clinical assessment of patient for dysmorphology. Tiong Yang Tan was involved with the development of the genetic testing and interpretation of results. Remi Kowalski was involved with cardiac assessments. Eva Morava contributed to the conception of the work. Joy Yapligo-Lee contributed to the initial assessment and conception of the work.

INFORMED CONSENT

Written and informed consent was obtained from the family for the genetic testing and publication. There was institutional approval for the use of galactose. All procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000.

ORCID

Sarah E. Donoghue https://orcid.org/0000-0002-1189-5060

REFERENCES

1. Stojkovic T, Vissing J, Petit F, et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med. 2009;361(4):425-427.
2. Morava E. Galactose supplementation in phosphoglucomutase-1 deficiency; review and outlook for a novel treatable CDG. Mol Genet Metab. 2014;112:275-279.
3. Thomson WHS, Maclaurin JC, Prineas JW. Skeletal muscle glycogenosis: an investigation of two similar cases. J Neurol Neurosurg Psychiatry. 1963;26:60-68.
4. Timal S, Hoischen A, Lehle L, et al. Gene identification in the congenital disorders of glycosylation type I by whole-exome sequencing. Hum Mol Genet. 2012;21(19):4151-4161.
5. Tegtmeier LC, Rust S, van Scherpenzeel M, et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med. 2014;370(6):533-542.
6. Wong SY, Beamer LJ, Gadomski T, et al. Defining the phenotype and assessing severity in phosphoglucomutase-1 deficiency. J Pediatr. 2016;175:130-136.
7. Wong SY, Gadomski T, van Scherpenzeel M, et al. Oral d-galactose supplementation in PGM1-CDG. Genet Med. 2017;19(11):1226-1235.
8. Tan TY, Gongza-Jauregui C, Bhoj EJ, et al. Monoallelic BMP2 variants predicted to result in haploinsufficiency cause craniofacial, skeletal, and cardiac features overlapping those of 20p12 deletions. Am J Hum Genet. 2017;101(6):985-994.
9. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
10. Voermans NC, Priesler N, Madsen KL, et al. PGM1 deficiency: substrate use during exercise and effect of treatment with galactose. Neuromuscul Disord. 2017;27:370-376.
11. Lowenthal N, Hain A, Parvari R, Hershkovitz E. Phosphoglucomutase-1 deficiency: intrafamilial clinical variability and common secondary adrenal insufficiency. Am J Med Genet Part A. 2015;167A:3139-3143.
12. Nolting K, Park JH, Tegtmeier LC, et al. Limitations of galactose therapy in phosphoglucomutase 1 deficiency. Mol Genet Metab Rep. 2017;13:33-40.
13. Fernlund E, Andersson O, Ellegård R, et al. The congenital disorder of glycosylation in PGM1 (PGM1-CDG) can cause severe cardiomyopathy and unexpected sudden cardiac death in childhood. Forensic Sci Int Genet. 2019;43:102111. https://doi.org/10.1016/j.fsigen.2019.06.012.

14. Zeevaert R, Scalais E, Muino Mosquera L, et al. De Schepper J PGM1 deficiency diagnosed during an endocrine work-up of low IGF-1 mediated growth failure. Acta Clin Belg. 2016;71(6):435-437.

15. Ondruskova N, Honzik T, Vondrackova A, et al. Glycogen storage disease-like phenotype with central nervous system involvement in a PGM1-CDG patient. Neuro Endocrin Lett. 2014;35(2):137-141.

16. Radenkovic S, Witters P, Morava E. Central nervous involvement is common in PGM1-CDG. Mol Genet Metab. 2018;125(3):200-204.

How to cite this article: Donoghue SE, White SM, Tan TY, Kowalski R, Morava E, Yaplioto-Lee J. Galactose treatment of a PGM1 patient presenting with restrictive cardiomyopathy. JIMD Reports. 2021;57:29–37. https://doi.org/10.1002/jmd2.12177